Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future

Diana V. Do

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter.

Original languageEnglish (US)
Pages (from-to)S24-S26
JournalOphthalmology
Volume116
Issue number10 SUPPL.
DOIs
StatePublished - Oct 1 2009

Fingerprint

Macular Degeneration
Choroidal Neovascularization
Disclosure
Vascular Endothelial Growth Factor A
Therapeutics
Quality of Life
Clinical Trials
Safety

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future. / Do, Diana V.

In: Ophthalmology, Vol. 116, No. 10 SUPPL., 01.10.2009, p. S24-S26.

Research output: Contribution to journalArticle

Do, Diana V. / Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future. In: Ophthalmology. 2009 ; Vol. 116, No. 10 SUPPL. pp. S24-S26.
@article{2c24ad3b22a64da7a4f6b70c1c867c78,
title = "Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future",
abstract = "Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter.",
author = "Do, {Diana V.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1016/j.ophtha.2009.06.049",
language = "English (US)",
volume = "116",
pages = "S24--S26",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future

AU - Do, Diana V.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter.

AB - Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter.

UR - http://www.scopus.com/inward/record.url?scp=70349469697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349469697&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2009.06.049

DO - 10.1016/j.ophtha.2009.06.049

M3 - Article

C2 - 19800536

AN - SCOPUS:70349469697

VL - 116

SP - S24-S26

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 10 SUPPL.

ER -